Suzuki Kazuhiro
Dept. of Urology, Graduate School of Medicine, Gunma University, Gunma, Japan.
Gan To Kagaku Ryoho. 2012 Oct;39(10):1467-70.
Docetaxel is used as a standard therapy for castration-resistant prostate cancer(CRPC). A recent report on the safety and efficacy of decetaxel, based on post-marketing surveillance in Japan, showed similar profiles of PSA response and adverse events. For the determination of efficacy, PSA 30% or 50% response, and an imaging examination are evaluated. One most understand the specific patterns of PSA levels, ie, PSA flare, the transient increase of PSA, and PSA stabilization. Docetaxel would be discontinued based on treatment efficacy, further treatment modalities, adverse events, etc. Now that new hormonal and cytotoxic agents are under development, we must accumulate clinical features of patients treated with docetaxel to construct a better future treatment strategy for CRPC.
多西他赛被用作去势抵抗性前列腺癌（CRPC）的标准治疗方法。最近一项基于日本上市后监测的关于多西他赛安全性和有效性的报告显示，其前列腺特异性抗原（PSA）反应和不良事件情况相似。为确定疗效，需评估PSA 30%或50%的反应以及影像学检查。人们必须了解PSA水平的具体模式，即PSA激增（PSA短暂升高）和PSA稳定。多西他赛将根据治疗效果、进一步的治疗方式、不良事件等情况停药。鉴于新的激素和细胞毒性药物正在研发中，我们必须积累接受多西他赛治疗患者的临床特征，以便构建更好的CRPC未来治疗策略。
